OncoMatch

OncoMatch/Clinical Trials/NCT06107920

Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy

Is NCT06107920 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Neoadjuvant chemotherapy for colon cancer.

Phase 3RecruitingUniversity Hospital, RouenNCT06107920Data as of May 2026

Treatment: Neoadjuvant chemotherapyThe aim of this study is to determine whether chemotherapy prior to tumor removal (neoadjuvant chemotherapy), in patients undergoing treatment for colon cancer in occlusion (CCO), would improve the rate of patients able to benefit from "optimal" treatment, i.e. complete treatment (including all neoadjuvant and adjuvant chemotherapy cures). This new strategy, which would combine chemotherapy before surgery and possibly post-operatively (depending on tumor analysis), could improve the prognosis of occluded colon cancers by treating circulating micrometastases and/or inducing a reduction in tumor size, thereby increasing the rate of complete resection.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

No prior chemotherapy

Cannot have received: abdominal or pelvic irradiation

No prior chemotherapy or abdominal or pelvic irradiation

Cannot have received: radiation therapy

Patient having received radiation therapy prior to surgery

Lab requirements

Blood counts

White blood cell count ≥ 3.109 /L with Neutrophils ≥ 1.5.109 / L, Platelet count ≥ 100.109 / L, Hemoglobin ≥ 9 g/dL (5.6 mmol/L)

Kidney function

Serum creatinine ≤ 1.5 x ULN (performed 10-15 days prior to randomization)

Liver function

Total bilirubin ≤ 1.5 x ULN, ASAT and ALAT ≤ 2.5 x ULN, Alkaline phosphatase ≤ 1.5 x ULN

Laboratory data including : White blood cell count ≥ 3.109 /L with Neutrophils ≥ 1,5.109 / L, Platelet count ≥ 100.109 / L, Hemoglobin ≥ 9 g/dL (5,6 mmol/L), Total bilirubin ≤ 1,5 x ULN (upper limit of normal), ASAT and ALAT ≤ 2,5 x ULN, Alkaline phosphatase ≤ 1,5 x ULN, Serum creatinine ≤ 1,5 x ULN (performed 10-15 days prior to randomization).

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify